Event
'My Hero & Me' webinar 2: From waste water to phage therapy: exploiting phage-antibiotic synergies from lab to patient
We are happy to announce the second ‘My hero and me’ webinar by Steven De Soir and Jeremy Barr. The webinar can be followed using the registration link above. Expect a contemporary view from Steven and his hero Jeremy on phage-antibiotic synergies.
With this initiative we aim to stimulate young researchers to get into contact with their scientific hero who is an inspiration source for their daily research, and to present jointly a seminar on their common topic. Simultaneously, we offer all of you an attractive webinar format to start or finish your working day.
After registration, you will receive a confirmation email containing information about joining the meeting.
Speakers
Jeremy Barr
Jeremy completed his PhD in microbiology at The University of Queensland in 2011. He then moved to San Diego, USA to complete a postdoctoral position with Prof. Forest Rohwer at San Diego State University. While there he studied the interactions of bacteriophage with mucosal surfaces and was involved in a word-first phage therapy case treating a patient with disseminated, multidrug-resistant infection. In 2016, he joined Monash University's School of Biological Sciences where he is currently a Senior Lecturer and Group Leader. His research group studies bacteriophages and their tripartite interactions with their bacterial hosts and the human body. In 2020, he joined the Centre to Impact AMR where he leads translational phage therapy work.
Steven De Soir
Steven obtained his Masters degree in Molecular & Cellular Biomedical Sciences in 2018 from the University of Antwerp after which he immediately started working on bacteriophages and their applications in a clinical setting at the LabMCT of the Queen Astrid Military Hospital in Brussels. Since 2020, he started his PhD-projected focusing on phage-antibiotic synergies in the setting of biofilm-related orthopedic infections. His work is part of a joint collaboration between the LabMCT and the Cellular & Molecular Pharmacology (FACM)-lab of the Louvain Drug Research Institute (LDRI) at the UCLouvain.
